MEDIPOST Inc. is a leading commercial-stage biotechnology company specializing in the development of umbilical cord-derived stem cell therapies to treat inflammation-driven degenerative diseases. The company's flagship product, CARTISTEM®, is the world's first allogeneic stem cell therapy, used to treat knee cartilage lesions caused by inflammation, approved in Korea in 2012 and used to treat over 30,000 patients. In the United States, CARTISTEM is entering late-stage development as a potential treatment for cartilage defects associated with knee osteoarthritis. In partnership with the Centre for Commercialization of Regenerative Medicine (CCRM), MEDIPOST has established OmniaBio, a cell and gene therapy contract development and manufacturing organization (CDMO) based in Hamilton, Ontario, to manufacture CARTISTEM. 

MEDIPOST Inc.

Brian Hosung Min

This department is responsible for overseeing and managing clinical research and development activities.

Clinical Development

This department provides strategic direction and oversight for the organization.

Executive Leadership

This department manages financial operations, including budgeting, accounting, and financial reporting.

Finance Department

This department manages employee relations, recruitment, and organizational development.

Human Resources

This department focuses on overseeing and optimizing operational processes while driving business development initiatives.

Operations and Development

This department ensures product quality and compliance through systematic testing and evaluation processes.

MEDIPOST Inc.

Org chart

Teams

Clinical Development

Executive Leadership

Finance Department

Human Resources

Operations and Development

Quality Assurance

Offices

MEDIPOST Inc.

Org chart

Teams

Clinical Development

Executive Leadership

Finance Department

Human Resources

Operations and Development

Quality Assurance

Offices

Related companies